No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema

Journal of Investigative Dermatology

Volumn 130, Issue 4, 2010, Pages 953-961

  Roelofzen, Judith H J ^a   Aben, Katja K H ^a,b   Oldenhof, Ursula T H ^a   Coenraads, Pieter Jan ^c   Alkemade, Hans A ^d   Van De Kerkhof, Peter C M ^a   Van Der Valk, Pieter G M ^a   Kiemeney, Lambertus A L M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Oost   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COAL TAR; CORTICOSTEROID; LIQUOR CARBONIS DETERGENS; PIX LITHANTRACIS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; ECZEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEOPLASM; OINTMENT; PRIORITY JOURNAL; PSORIASIS; QUESTIONNAIRE; REGISTER; RISK ASSESSMENT; SIDE EFFECT; SKIN CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COAL TAR; ECZEMA; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KERATOLYTIC AGENTS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PSORIASIS; QUESTIONNAIRES; RISK FACTORS; YOUNG ADULT;

EID: 77949539891     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.389     Document Type: Article

References (38)

1. Arellano F (1997) Risk of cancer with cyclosporine in psoriasis. Int J Dermatol 36(Suppl 1):15-17
2. Berger EM, Gottlieb AB (2007) Developments in systemic immunomodulatory therapy for psoriasis. Curr Opin Pharmacol 7:434-444
3. Bickers DR. (1981) The carcinogenicity and mutagenicity of therapeutic coal tar: a perspective. J Invest Dermatol 77:173-174
4. Boffetta P, Jourenkova N, Gustavsson P (1997) Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 8:444-472
5. Donato F, Monarca S, Marchionna G et al. (2000) Mortality from cancer and chronic respiratory diseases among workers who manufacture carbon electrodes. Occup Environ Med 57:484-487
6. Donders AR, van der Heijden GJ, Stijnen T et al. (2006) Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 59:1087-1091
7. Enderlein E, Meller S, Rieker J et al. (2005) Current aspects of the therapy with topical calcineurin inhibitors. Hautarzt 56:937-941
8. Greaves MW, Weinstein GD (1995) Treatment of psoriasis. N Engl J Med 332:581-588
9. Hannuksela-Svahn A, Pukkala E, Laara E et al. (2000) Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 114:587-590
10. IARC (1985) Polynuclear aromatic compounds, part 4, bitumens, coal-tars and derived products, shale-oils and soots. IARC, Monograph Eval Carcinog Risk Chem Humans 35:83-159
11. Jensen P, Hansen S, Moller B et al. (1999) Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 40:177-186
12. Jones SK, Mackie RM, Hole DJ et al. (1985) Further evidence of the safety of tar in the management of psoriasis. Br J Dermatol 113:97-101
13. Larko O, Swanbeck G (1982) Is UVB treatment of psoriasis safe? A study of extensively UVB-treated psoriasis patients compared with a matched control group. Acta Derm Venereol 62:507-512
14. Lebwohl M (2003) Psoriasis. Lancet 361:1197-1204
15. Lindelof B, Sigurgeirsson B, Gabel H et al. (2000) Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143:513-519
16. Lindelof B, Sigurgeirsson B, Tegner E et al. (1999) PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 141:108-112
17. London NJ, Farmery SM, Will EJ et al. (1995) Risk of neoplasia in renal transplant patients. Lancet 346:403-406
18. Marcil I, Stern RS (2001) Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 358:1042-1045
19. Marston CP, Pereira C, Ferguson J et al. (2001) Effect of a complex environmental mixture from coal tar containing polycyclic aromatic hydrocarbons (PAH) on the tumor initiation, PAH-DNA binding and metabolic activation of carcinogenic PAH in mouse epidermis. Carcinogenesis 22:1077-1086
20. Maughan WZ, Muller SA, Perry HO et al. (1980) Incidence of skin cancers in patients with atopic dermatitis treated with coal tar. A 25-year follow-up study. J Am Acad Dermatol 3:612-615
21. Menter A, Gottlieb A, Feldman SR et al. (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:826-850
22. Menter A, Griffiths CE (2007) Current and future management of psoriasis. Lancet 370:272-284
23. Moloney FJ, Comber H, O'Lorcain P et al. (2006) A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 154:498-504
24. Moons KG, Donders RA, Stijnen T et al. (2006) Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol 59:1092-1101
25. Mrowietz U, Rott S (2007) Evaluating topical treatments in severe psoriasis. Eur Dermatol Rev 1:23-24
26. Nijsten TE, Stern RS (2003) The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 121:252-258
27. Paghdal KV, Schwartz RA (2009) Topical tar: back to the future. J Am Acad Dermatol 61:294-302
28. Partanen T, Boffetta P (1994) Cancer risk in asphalt workers and roofers: review and meta-analysis of epidemiologic studies. Am J Ind Med 26:721-740
29. Paul CF, Ho VC, McGeown C et al. (2003) Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120:211-216
30. Pittelkow MR, Perry HO, Muller SA et al. (1981) Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. Arch Dermatol 117:465-468
31. Ramsay HM, Fryer AA, Reece S et al. (2000) Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 36:167-176
32. Ring J, Barker J, Behrendt H et al. (2005) Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 19:663-671
33. Roelofzen JH, Aben KK, Khawar AJ et al. (2007) Treatment policy for psoriasis and eczema: a survey among dermatologists in the Netherlands and Belgian Flanders. Eur J Dermatol 17:416-421
34. Ronckers CM (2001) Long-term health effects of nasopharyngeal radium irradiation. Thesis, NKI, Amsterdam
35. Stern RS, Liebman EJ, Vakeva L (1998) Oral psoralen| and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA follow-up study. J Natl Cancer Inst 90:1278-1284
36. Stern RS, Zierler S, Parrish JA (1980) Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1:732-735
37. Tsai PJ, Shieh HY, Lee WJ et al. (2001) Health-risk assessment for workers exposed to polycyclic aromatic hydrocarbons (PAHs) in a carbon black manufacturing industry. Sci Total Environ 278:137-150
38. van der Heijden GJ, Donders AR, Stijnen T et al. (2006) Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. J Clin Epidemiol 59:1102-1109